---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-012868"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2025-02-04T23:59:59+00:00"
generated_at: "2026-05-27T03:24:49.185391+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PTAB invalidates Atossa's US Patent 11,572,334; new patent 12,201,591 issued

## Summary
- PTAB final decision found all claims of US Patent 11,572,334 unpatentable; Atossa will not appeal.
- Atossa issued new US Patent 12,201,591 (Sustained Release Compositions of Endoxifen) with 31 claims.
- Company states decision has no impact on current clinical formulations; will pursue continuation patent application.
- Patent estate now includes four issued US patents covering formulations in development.

## SEC filing metadata
- accession: 0000950170-25-012868
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2025-02-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000095017025012868/0000950170-25-012868-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000095017025012868/atos-20250130.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-012868
- JSON: https://secwatch.observer/filing/0000950170-25-012868.json
- Plain text: https://secwatch.observer/filing/0000950170-25-012868.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.